Adverse Drug Reactions in COVID-19 patients admitted to Intensive care unit: Analysis of individual case study reports

Nazir, Nazia; Chopra, Deepti; Sidhu, Jaspreet Kaur; Bhandari, Bharti

doi:10.21203/rs.3.rs-596922/v1

Cited by 2 publications

(1 citation statement)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…В одном из обсервационных исследований не было выявлено значимой связи между возрастом и возникновением НР при терапии COVID-19 [11]. В нашем исследовании мы обнаружили, что пациенты, у которых возникло ЛПП, в среднем имели более молодой возраст по сравнению с группой, в которой у пациентов не развилось данной НР.…”

Section: Introductionunclassified

Model for predicting risk of developing drug-induced liver injury during remdesivir therapy: observational prospective open case-control study

Shevchuk,

Kryukov,

Temirbulatov

et al. 2023

Farm. farmakol. (Pâtigorsk)

View full text Add to dashboard Cite

Remdesivir is a drug widely used for the etiotropic treatment of COVID-19. According to a number of studies, the incidence of adverse reactions during remdesivir therapy reaches 66%, with the most common is an increase in liver function tests.The aim of the work was to study the influence of clinical, demographic and pharmacogenetic factors on the development of drug-induced liver damage during remdesivir therapy in COVID-19 patients.Materials and methods. The study comprised 100 hospitalized patients treated with remdesivir. The patients were divided into two groups: group 1 (n=32) – remdesivir therapy, developed an increase in the level of liver transaminases; group 2 (control, n=68) – did not develop this adverse reaction. The patients in both groups underwent a pharmacogenetic study, and a retrospective analysis of medical records was performed. Based on the data obtained, the association of clinical, laboratory, pharmacological and pharmacogenetic parameters with the development of drug-induced liver damage during remdesivir therapy was studied.Results. In the group of patients with the development of drug-induced liver damage, people with a high body mass index were significantly more likely than in the control group (30.7±4.2 kg/m2 in group 1 vs. 27.3±5.5 kg/m2 in group 2, p=0.003), with a history of diabetes mellitus (odds ratio (OR)=2.647, 95% confidence interval (CI)=1.092–6.414, χ2=4.785, p=0.029), with higher levels of ferritin in the blood (724.03±432.27 and 553.19±358.48 mg/mol, respectively, p=0.040), receiving therapy with angiotensin-converting enzyme inhibitors (OR=5.440, 95% CI=2.160–13.699, χ2=14.027, p=0.000), statins (OR=3.148, 95% CI=1.307–7.581, χ2=6.795, p=0.009), and also being heterozygous for the polymorphic marker rs776746 of the CYP3A5 gene (OR=3.961, 95% CI=1.343–11.686, χ2=6.772, p=0.009).Conclusion. A high body mass index, a history of diabetes mellitus, high levels of ferritin in the blood, concomitant therapy with angiotensin-converting enzyme inhibitors and statins, as well as a carriage of the AG genotype for the polymorphic marker rs776746 of the CYP3A5 gene increase the likelihood of developing drug-induced liver damage during remdesivir therapy. In this regard, it is necessary to consider these factors when prescribing remdesivir therapy, conduct a more careful monitoring of clinical and laboratory indicators of liver damage, and develop personalized approaches to the treatment of COVID-19 patients.

show abstract

Section: Introductionunclassified

Model for predicting risk of developing drug-induced liver injury during remdesivir therapy: observational prospective open case-control study

Shevchuk,

Kryukov,

Temirbulatov

et al. 2023

Farm. farmakol. (Pâtigorsk)

View full text Add to dashboard Cite

show abstract

Detection of Adverse Drug Reactions in COVID-19 Hospitalized Patients in Saudi Arabia: A Retrospective Study by ADR Prompt Indicators

et al. 2023

View full text Add to dashboard Cite

Seeking an alternative approach for detecting adverse drug reactions (ADRs) in coronavirus patients (COVID-19) and enhancing drug safety, a retrospective study of six months was conducted utilizing an electronic medical record (EMR) database to detect ADRs in hospitalized patients for COVID-19, using “ADR prompt indicators” (APIs). Consequently, confirmed ADRs were subjected to multifaceted analyses, such as demographic attribution, relationship with specific drugs and implication for organs and systems of the body, incidence rate, type, severity, and preventability of ADR. The incidence rate of ADRs is 37%, the predisposition of organs and systems to ADR is observed remarkably in the hepatobiliary and gastrointestinal systems at 41.8% vs. 36.2%, p < 0.0001, and the classes of drugs implicated in the ADRs are lopinavir-ritonavir 16.3%, antibiotics 24.1%, and hydroxychloroquine12.8%. Furthermore, the duration of hospitalization and polypharmacy are significantly higher in patients with ADRs at 14.13 ± 7.87 versus 9.55 ± 7.90, p < 0.001, and 9.74 ± 5.51 versus 6.98 ± 4.36, p < 0.0001, respectively. Comorbidities are detected in 42.5% of patients and 75.2%, of patients with DM, and HTN, displaying significant ADRs, p-value < 0.05. This is a symbolic study providing a comprehensive acquaintance of the importance of APIs in detecting hospitalized ADRs, revealing increased detection rates and robust assertive values with insignificant costs, incorporating the hospital EMR database, and enhancing transparency and time effectiveness.

show abstract

Adverse Drug Reactions in COVID-19 patients admitted to Intensive care unit: Analysis of individual case study reports

Cited by 2 publications

References 12 publications

Model for predicting risk of developing drug-induced liver injury during remdesivir therapy: observational prospective open case-control study

Model for predicting risk of developing drug-induced liver injury during remdesivir therapy: observational prospective open case-control study

Detection of Adverse Drug Reactions in COVID-19 Hospitalized Patients in Saudi Arabia: A Retrospective Study by ADR Prompt Indicators

Contact Info

Product

Resources

About